North Chicago Business
-
Abbott partner Astellas rejected by top court on Omnicef patentJan 10, 2010 10:00 pm - The U.S. Supreme Court let stand a ruling permitting the sale of generic versions of Abbott Laboratories' Omnicef antibiotic, in a victory for Teva Pharmaceutical Indust...
-
Boston Scientific stent inferior to Abbott Lab's, study saysJan 07, 2010 10:00 pm - Boston Scientific Corp.'s Taxus Liberte stent shouldn't be used in routine clinical practice because it's inferior in terms of safety and efficacy to Abbott Laboratories...
-
Market rally ignored most profitable, stable companiesDec 27, 2009 10:00 pm - Brown-Forman Corp.'s Paul Varga and Johnson & Johnson's William Weldon are among chief executive officers left behind in the 2009 stock-market rebound even after they cr...
-
Abbott sues Apotex over weight-loss drug MeridiaDec 23, 2009 10:00 pm - Abbott Laboratories, the U.S. health-care product maker with $29.5 billion in sales last year, accused Canada’s Apotex Inc. in a lawsuit of infringing a patent for the...
-
Abbott seeks EU approval to buy Solvay pharmaceuticals unitDec 20, 2009 10:00 pm - Abbott Laboratories sought European Union approval to purchase Solvay SA's pharmaceuticals unit, the European Commission said in an e-mailed statement today. The commis...
-
Abbott settles patent suit over TriCor with TevaNov 29, 2009 10:00 pm - Abbott Laboratories said Teva Pharmaceutical Industries Ltd. won't sell the 145-milligram version of Abbott's TriCor cholesterol-lowering drug until at least 2011 under ...
-
Abbott's Niaspan beats Merck's Zetia in studyNov 15, 2009 10:00 pm - Boosting artery-clearing good cholesterol with Abbott Laboratories' Niaspan worked better at opening clogged vessels than reducing bad cholesterol with Merck & Co.'s Zet...
-
Abbott faces probe over marketing of DepakoteNov 05, 2009 10:00 pm - Abbott Laboratories said it is being investigated by the U.S. Justice Department over "sales and marketing activities" for Depakote, its third top-selling drug. The inve...
-
Judge upholds Abbott's $1.67 billion patent suit loss to J&JNov 04, 2009 10:00 pm - Abbott Laboratories failed to convince a federal judge to throw out a record $1.67 billion verdict won by Johnson & Johnson's Centocor unit in a suit over an arthritis d...
-
Study: Abbott's Niaspan reduces arteries' plaque buildupNov 01, 2009 10:00 pm - Combining Abbott Laboratories' cholesterol pill Niaspan with an older medicine, called a statin, reduced plaque buildup more than the statin alone, a study found. Patien...